ArticleBiochemical genetics2026
Identification and Verification of SLC6A15 Involved in Keloid via Bioinformatics Analysis and Machine Learning.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A panoramic analysis of keloid pathogenesis: multidimensional network regulation of genetics-immunity-metabolism-mechanical force.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Keloid is a fibroproliferative disorder that poses a challenge in clinical management. This study aims to identify and functionally annotate differentially expressed genes (DEGs) in keloid and explore the potential role of SLC6A15. The data were obtained from GEO (GSE218922 and GSE7890), and the DEGs and module genes were obtained with Limma and WGCNA. KEGG and GO enrichment analysis, and machine learning algorithms (Random Forest, Boruta, and XGBoost) were conducted to explore the keloid-related key genes. Finally, qRT-PCR was carried out to detect SLC6A15 mRNA expression, and CCK-8 and flow cytometry were employed to assess cell proliferation and apoptosis. We obtained 147 DEGs between keloid fibroblasts and normal fibroblasts, and 193 DEGs between keloid stem cells and normal stem cells, followed by acquisition of 40 intersection DEGs. These intersection DEGs were mainly enriched in external encapsulating structure organization, extracellular matrix organization, and were closely related to cytoskeleton in muscle cells and arrhythmogenic right ventricular cardiomyopathy (ARVC). WGCNA analysis identified five modules, with the blue modules showing a significant negative correlation with keloid. Afterwards, three machine learning methods were applied to analyze DEGs in keloid, identifying SLC6A15 as the most important gene. Further validation demonstrated that SLC6A15 was lowly expressed in keloid tissues and fibroblasts, and SLC6A15 overexpression inhibited proliferation and facilitated apoptosis in keloid fibroblasts. This study identified SLC6A15 as a potential biomarker for keloid, providing new research clues for the treatment target of this disorder.
Indexed as
Identifiers
40742424What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.